Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Medspoke's Talks
Medspoke
Medspoke
Clinical Cancer Research
Published September 9, 2026
Neoadjuvant Pertuzumab Biosimilar HLX11 Versus Reference Pertuzumab for Early-stage or Locally Ad...
September 10, 2026
Medspoke
Medspoke
Journal of Clinical Oncology
Published September 9, 2026
00:00
--:--
Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Posi...
September 10, 2026
Share
Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer.
https://www.medspoke.co/channel_journal?id=795&tap_id=13692
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Medspoke
Medspoke
Clinical Breast Cancer
Published August 13, 2026
Self-Reported Compliance With Adjuvant Endocrine Therapy in Young Women With Hormone Receptor-Pos...
September 10, 2026
Why are you reporting this TALK?
